

## **Supplemental Material to:**


Jingyi Yang, Maohua Zhong, Yan Zhang, Ejuan Zhang, Ying Sun, Yuan Cao, Yaoming Li, Dihan Zhou, Benxia He, Yaoqing Chen, Yi Yang, Jie Yu and Huimin Yan

Antigen replacement of domains
D2 and D3 in flagellin promotes mucosal
IgA production and attenuates flagellin-induced
inflammatory response after intranasal immunization

2013; 9(5) http://dx.doi.org/10.4161/hv.23809


www.landesbioscience.com/journals/vaccines/article/23809

## Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization




**Figure S1.** Flagellins with replaced D2 and D3 domains show similar TLR5 agonist efficacy. (A) Schematic diagram showing domain structures and variants. KFD-p24 2A / 2B / 2C / 2D / 3A / 3B / 3C. (B) IL-8 and (C) MCP-1 in the cell culture supernatants of Caco-2 cells 6-h post KFD-p24

stimulation were tested by ELISA. Data are presented as the means  $\pm$  SEM from triplicates of one experiment that was repeated three times.



**Figure S2.** KFD-p24 3D induced less of a systemic inflammatory response after intra-peritoneal administration than did KF-p24. C57BL/6 mice were injected intraperitoneally with p24, KFD-p24 3D or KF-p24 in 250μl PBS. (A) and (B) IL-6 and KC in serum were tested by ELISA 4h after 10 μg, 50 μg or 250 μg of stimulus administration. (C) and (D) Time-course of IL-6 and KC in serum were tested by ELISA after administration. (E) Time-course of body mass changes after administration. (F) Compared with the control group (250 μg p24) the fold changes of serum transaminase level were evaluated 24 h post-administration i.p. Data are presented as the means ± SEM from one experiment that was repeated three times (n=6 per group).



**Figure S3.** Domains D2 and D3 constitute the main antigenicity region of KF. A series of KF-derived flagellin was generated and coated to test the IgG titers of serum from BALB/c mice pre-immunized intranasally at 0, 4<sup>th</sup>, or 8<sup>th</sup> weeks with 5 μg KF plus 5 μg OVA or 5μg KF alone. (A) and (B) Schematic diagram and SDS-PAGE of a different KF variant. KFR: domain D2 and D3 of KF re-inserted into KFD1. (B) SDS-PAGE of a different KF variant. (C) Ratios of different KF variant-specific serum IgG titer to KF specific IgG titer. Data are presented as the means ± SEM of one experiment that was repeated three times.